MRK - Merck & Co

-

$undefined

N/A

(N/A)

Merck & Co NYSE:MRK Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Location: 126 East Lincoln Avenue, Rahway, NJ, 07065, United States | Website: https://www.merck.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

216.7B

Cash

9.228B

Avg Qtr Burn

N/A

Short % of Float

1.48%

Insider Ownership

0.06%

Institutional Own.

80.83%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

KEYTRUDA+ chemotherapy Details
Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma

Approved

Update

GARDASIL 9 Details
Human Papillomavirus 9-valent Vaccine, Human papillomavirus

Approved

Update

KEYTRUDA Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Update

Approved

Update

TUKYSA (Tucatinib) Details
Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

PREVYMIS™ (letermovir) Details
Cytomegalovirus, Viral infection

Approved

Quarterly sales

Approved

Quarterly sales

KEYTRUDA+ trastuzumab+ chemotherapy Details
Gastric cancer, Cancer, Gastroesophageal adenocarcinomas

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Biliary Tract Cancer

Approved

Quarterly sales

CAPVAXIVE (V116) Details
Pneumococcal Conjugate Vaccine

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

WELIREG® (belzutifan) Details
Renal cell carcinoma, von Hippel-Lindau, Cancer, Hemangioblastoma, Pancreatic neuroendocrine tumors

Approved

Quarterly sales

KEYTRUDA + chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

WELIREG® (belzutifan) Details
Pheochromocytoma , Paraganglioma

Approved

Quarterly sales

LYNPARZA(olaparib) + abi/pred Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

KEYTRUDA in comb w/chemotherapy Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

WINREVAIR (sotatercept-csrk) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

KEYTRUDA +carboplatin + paclitaxel Details
Cancer, Solid tumor/s, Carcinoma , Endometrial cancer

Approved

Quarterly sales

KEYTRUDA (pembrolizumab) injection Details
Gastric cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

KEYTRUDA + Berahyaluronidase Alfa Details
Non-small cell lung carcinoma

PDUFA

Approval decision

KEYTRUDA® (pembrolizumab) Details
Head and neck squamous cell carcinoma, Cancer

PDUFA

Approval decision

Clesrovimab (MK-1654) Details
Respiratory syncytial virus

PDUFA

Approval decision

Patritumab deruxtecan (HER3-DXd) Details
Non-small cell lung carcinoma

BLA

Resubmission

Islatravir+ Doravirine Details
Viral infection, Human immunodeficiency virus

BLA

Submission

NDA

FDA meeting

Bomedemstat Details
Thrombocytopenia

Phase 3

Data readout

MK-2870 Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Nemtabrutinib Details
Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 3

Data readout

MK-5684 (ODM-208) Details
Cancer, Castration-resistant prostate cancer

Phase 3

Data readout

Phase 3

Data readout

Bomedemstat Details
Thrombocythemia

Phase 3

Data readout

Ifinatamab Deruxtecan (I-DXd) Details
Small cell lung cancer, Cancer

Phase 3

Data readout

LAGEVRIO™ (molnupiravir) Details
Viral infection, COVID-19

Phase 3

Data readout

KEYTRUDA+pemetrexed Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

MK-1084 +KEYTRUDA® Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Tulisokibart (MK-7240) (PRA023) (Anti-TL1A mAb) Details
Irritable bowel syndrome, Crohns disease, Ulcerative colitis

Phase 3

Data readout

MK-0616 Details
Cardiovascular disease , Hypercholesterolemia

Phase 3

Data readout

Clesrovimab (MK-1654) Details
Respiratory syncytial virus

Phase 3

Data readout

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Carcinoma , Endometrial cancer

Phase 3

Update

Zilovertamab (MK-2140) Details
Diffuse large B cell lymphoma

Phase 3

Update

KEYTRUDA + favezelimab Details
Cancer, Metastatic colorectal cancer

Phase 3

Update

KEYTRUDA Details
Cancer, Renal cell carcinoma

Phase 3

Update

KEYTRUDA Details
Cancer, Solid tumor/s, Urothelial carcinoma

Phase 3

Update

KEYTRUDA + LENVIMA Details
Cancer, Renal cell carcinoma

Phase 3

Update

Phase 3

Update

KEYTRUDA Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer

Phase 3

Update

Phase 3

Update

KEYTRUDA + LENVIMA in comb w/TACE Details
Cancer, Hepatocellular carcinoma

Phase 3

Update

KEYTRUDA Details
Cancer, Solid tumor/s, ER+/HER2- breast cancer

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

MK-0616 Details
Hypercholesterolemia

Phase 3

Initiation

Raludotatug Deruxtecan Details
Platinum-resistant ovarian cancer, Cancer

Phase 2/3

Data readout

Restoret (MK-3000, formerly EYE103) Details
Eye disease , Diabetic macular edema

Phase 2/3

Data readout

Efinopegdutide (MK-6024) Details
Non-Alcoholic Fatty Liver Disease, Liver disease

Phase 2b

Initiation

Phase 2

Data readout

Phase 2

Data readout

Belzutifan + cabozantinib Details
Cancer, Renal cell carcinoma

Phase 2

Update

PRA023 (Anti-TL1A mAb) Details
Autoimmune disease, Systemic sclerosis

Phase 2

Update

Ifinatamab Deruxtecan (I-DXd) Details
Small cell lung cancer, Cancer

Phase 2

Update

PRA023 (Anti-TL1A mAb) Details
Systemic sclerosis, Autoimmune disease

Phase 2

Update

HPN328 (DLL3) +/- atezolizumab Details
Cancer, Small cell lung cancer, Solid tumor/s

Phase 1/2

Update

PRA052 Details
Inflammatory bowel disease

Phase 1

Update

HPN217 (BCMA) Details
Multiple myeloma

Phase 1

Update

KEYTRUDA + LENVIMA Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Failed

Discontinued